Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee
- Published
- May 2nd, 2019
- Type
- Staff Publication
- Topic
- Abortion
- Authors
- Mark, A., Foster, M.A., Grossman, D., Prager, S.W., Reeves, M., Velásquez, C.V., Winikoff, B.
Early abortion continues to expand outside of traditional clinics, through telemedicine, self-managed medication abortion, or in smaller offices that do not specialize in obstetrical care. Consequently, requiring Rh testing and anti-D immunoglobulin as part of abortion care is becoming a barrier. As of early 2019, the Society of Family Planning [1], the American College of Obstetricians and Gynecologists [2], and the Society of Obstetricians and Gynecologists of Canada [3] recommend that all Rh D-negative women receive anti-D immunoglobulin after an induced abortion, regardless of gestational age or type of procedure.
Access the abstract.